Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of haNK alone or haNK combined with convalescent plasma in mild-to-moderate Covid-19 infection

Next Previous
Trial Profile

A clinical trial of haNK alone or haNK combined with convalescent plasma in mild-to-moderate Covid-19 infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 20 Apr 2020 New trial record
  • 14 Apr 2020 According to an NantKwest, ImmunityBio media release, this study is anticipated to begin in this quarter.
  • 14 Apr 2020 According to an NantKwest, ImmunityBio media release, the companies within the NantWorks family of companies, today announced that they are in active discussions with the U.S. Food and Drug Administration (FDA) for vaccines and therapeutics to combat COVID-19. The company announces intention to submit IND application to the U.S FDA for Covid-2019 infections.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top